Rifabutin

證據等級: L5

預測適應症: 10 個

Rifabutin: From Mycobacterial Infection to HIV Infectious Disease

One-Sentence Summary

Rifabutin is a rifamycin-class antimycobacterial, established as standard therapy for preventing/treating Mycobacterium avium complex (MAC) bacteremia and for treating tuberculosis in patients co-infected with HIV. The TxGNN model predicts a link to HIV infectious disease, but this is supported almost entirely by evidence around rifabutin's existing role managing HIV-associated opportunistic infections — with 39 clinical trials and 20 publications in the evidence base, not new antiretroviral activity.

Quick Overview

Item	Content
Original Indication	Mycobacterial infections (MAC prophylaxis/treatment, TB in HIV co-infection) — formal DrugBank/regulatory indication text is a data gap (see below)
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.88%
Evidence Level	L1
New Zealand Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank MOA query returned a data gap). Based on known information, rifabutin is part of the rifamycin antibiotic class (structurally related to rifampicin), inhibiting bacterial DNA-dependent RNA polymerase. Its efficacy against Mycobacterium avium complex and M. tuberculosis has been proven over decades of use, and it is specifically favored over rifampicin in HIV-positive patients because it is a weaker CYP3A4 inducer, causing fewer disruptive interactions with protease inhibitors and integrase inhibitors used in antiretroviral therapy (ART).

The predicted link to "HIV infectious disease" should be read carefully: rifabutin has no direct antiretroviral activity and does not treat HIV itself. Its relevance to HIV infection is as the standard-of-care agent for managing HIV-associated opportunistic mycobacterial disease — MAC bacteremia prophylaxis/treatment and TB treatment in HIV/TB co-infected patients — which is why the overwhelming majority of trials and literature in this evidence pack concern rifabutin's use in HIV-positive populations (often as pharmacokinetic drug-drug interaction studies with ART) rather than a genuinely novel repurposing signal. The evidence pack's own reviewer notes flag this as a potentially misleading label, and the correct framing is "HIV-related opportunistic infection management" rather than treatment of HIV infection itself.

Mechanistically, this is why the evidence level still reaches L1: multiple completed Phase 3 RCTs (MAC prevention/treatment trials, several hundred to over a thousand patients each) substantiate rifabutin's established efficacy in this HIV-adjacent clinical context, even though it does not represent a new mechanism against HIV.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00002080	N/A	Completed	N/A	Daily rifabutin monotherapy to prevent/delay MAC bacteremia in HIV+ patients with CD4 ≤200 — core evidence for rifabutin's established HIV-adjacent indication (relevance grade A)
NCT00001030	Phase 3	Completed	1,100	Clarithromycin vs. rifabutin vs. combination for prevention of MAC bacteremia/disseminated disease in advanced HIV; also assessed survival, toxicity, QoL
NCT00002101	Phase 3	Completed	450	Clarithromycin/ethambutol ± rifabutin (300mg or 450mg) vs. placebo for treatment of MAC bacteremia; measured CFU reduction and survival
NCT00002122	Phase 3	Completed	720	Azithromycin and rifabutin, alone and combined, for prevention of disseminated MAC in HIV-infected patients
NCT00001047	Phase 3	Completed	400	Clarithromycin + ethambutol with rifabutin or clofazimine for disseminated MAC disease in AIDS patients
NCT00002032	N/A	Completed	750	Double-blind, placebo-controlled trial of oral rifabutin for prevention of MAC bacteremia in AIDS patients with CD4 ≤200
NCT00002267	N/A	Completed	750	Double-blind, placebo-controlled trial assessing rifabutin monotherapy safety/efficacy in delaying MAC bacteremia incidence
NCT00640887	Phase 2	Completed	48	Rifabutin as replacement for rifampicin in combined TB/HIV treatment across different ART regimens (South Africa)
NCT00023400	Phase 4	Completed	20	TBTC study of nelfinavir-rifabutin PK interaction in HIV-related TB patients on a rifabutin-based regimen
NCT04518228	N/A	Completed	205	PK properties of antiretroviral and anti-TB drugs, including rifabutin, during pregnancy and postpartum in HIV/TB co-infected women

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23828580	2013	Systematic Review (Cochrane)	Cochrane Database Syst Rev	Rifamycins (rifampicin/rifabutin/rifapentine) vs. isoniazid for preventing active TB in people at risk of latent infection
21726477	2009	Review	BMJ Clinical Evidence	Overview of TB treatment in HIV-infected patients, including rifamycin-based regimens
28233512	2017	Review	Microbiology Spectrum	Bidirectional TB-HIV disease relationship and treatment considerations, incl. rifabutin as lower-interaction rifamycin
40310456	2025	Review	PNAS	Next-generation rifamycins for mycobacterial infections; discusses rifabutin's CYP3A4 induction and limitations
33294914	2021	Cohort	J Antimicrob Chemother	Rifabutin PK and safety in TB/HIV-coinfected children on lopinavir/ritonavir-based second-line ART; neutropenia noted
31139825	2019	Cohort	J Antimicrob Chemother	Safety and efficacy of rifabutin in HIV/TB-coinfected children on lopinavir/ritonavir-based ART
25281400	2015	Cohort	J Antimicrob Chemother	PK and safety of rifabutin in young HIV-infected children co-treated with lopinavir/ritonavir
26832753	2016	Population PK Analysis	J Antimicrob Chemother	Pooled analysis of rifabutin-HIV protease inhibitor drug-drug interactions to guide dosing
36385424	2023	Population PK Model	Br J Clin Pharmacol	Rifabutin-dolutegravir interaction model, supporting rifabutin as an alternative to rifampicin in HIV/TB co-treatment
32979587	2020	Retrospective Observational	Int J Infect Dis	Tenofovir alafenamide + rifabutin co-administration did not compromise HIV-1 viral suppression

New Zealand Market Information

RIFABUTIN currently holds no marketing authorizations in New Zealand (0 licenses on file; market status: not marketed).

Safety Considerations

Please refer to the package insert for safety information — key warnings, contraindications, and DDI data are all unavailable in this evidence pack (query returned no TFDA/DDI records).

One point worth flagging despite the data gap: the trial and literature base above is dominated by pharmacokinetic drug-drug interaction studies with antiretrovirals (protease inhibitors, integrase inhibitors, NNRTIs), reflecting rifabutin's known CYP3A4-mediated interaction profile — this should be a priority focus once formal DDI/label data is obtained.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 RCTs (several hundred to over a thousand patients) substantiate rifabutin's established efficacy for MAC bacteremia prophylaxis/treatment and HIV/TB co-treatment, supporting the L1 evidence level. However, the "HIV infectious disease" label is potentially misleading — rifabutin manages HIV-associated opportunistic infection rather than HIV itself — and the drug is not currently marketed in New Zealand, with two outstanding data gaps blocking a full safety assessment.

To proceed, the following is needed:

TFDA/Medsafe package insert warnings and contraindications (DG001, blocking — required before any S1 safety evaluation)
Detailed mechanism of action data from DrugBank (DG002, high priority)
Reframing of the target indication to "HIV-related opportunistic infection (MAC/TB) management" to avoid mislabeling as direct anti-HIV therapy
A regulatory pathway assessment for New Zealand market entry, given current non-marketed status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.